Can CVS Health Buy BioPharmX Corporation? - CWEB.com
Can CVS Health Buy BioPharmX Corporation? - CWEB.com
- Corporate health-care deal value surged 37 percent last year, according to a new report from consulting firm Bain & Company.
- The number of health-care mergers and acquisitions rose 16 percent.
- CVS Health's planned acquisition of health insurer Aetna was the largest corporate deal of 2017 at $69 billion.
- Financial Health: Does it have a healthy balance sheet?
- Management:Have insiders been ramping up their shares to take advantage of the market’s sentiment for BPMX’s future outlook?
- Other High-Growth Alternatives: BPMX is a high-growth stock you could be holding?
Owner Name | Date | Shared Held | Change (Shares) | Change (%) | Value (in 1,000s) |
---|---|---|---|---|---|
VIVO CAPITAL, LLC | 05/13/2018 | 16,128,515 | 2,328,571 | 16.87 | 3,306 |
FRANKLIN RESOURCES INC | 05/13/2018 | 9,749,615 | 0 | 0.00 | 1,999 |
VANGUARD GROUP INC | 05/13/2018 | 5,498,918 | 3,541,971 | 181.00 | 1,127 |
GEODE CAPITAL MANAGEMENT, LLC | 03/31/2018 | 671,686 | 347,719 | 107.33 | 138 |
VIRTU FINANCIAL LLC | 03/31/2018 | 426,837 | 426,837 | New | 88 |
BARCLAYS PLC | 03/31/2018 | 362,900 | 362,900 | New | 74 |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 03/31/2018 | 181,335 | 181,335 | New | 37 |
CITADEL ADVISORS LLC | 03/31/2018 | 146,859 | 146,859 | New | 30 |
MCF ADVISORS LLC | 03/31/2018 | 105,629 | 105,629 | New | 22 |
JANE STREET GROUP, LLC | 03/31/2018 | 96,941 | 96,941 | New | 20 |
TWO SIGMA SECURITIES, LLC | 03/31/2018 | 93,390 | 47,105 | 101.77 | 19 |
NORTHERN TRUST CORP | 03/31/2018 | 92,518 | 0 | 0.00 | 19 |
UBS GROUP AG | 03/31/2018 | 70,367 | 36,614 | 108.48 | 14 |
LADENBURG THALMANN FINANCIAL SERVICES INC. | 03/31/2018 | 64,200 | 0 | 0.00 | 13 |
CREDIT SUISSE AG/ | 03/31/2018 | 50,000 | 50,000 | New | 10 |
HOLDERS | SHARES | |
Increased Positions | 17 | 7,708,826 |
Held Positions | 7 | 15,447,095 |
Total Institutional Shares | 27 | 33,878,519 |
Strong Institutional Ownership
Institutions own approximately 19.42% of BioPharmX’ shares. Among active positions in the latest quarter, 7 holders increased their positions by a total of 10.8 million shares. This means there is a net increase in ownership of 9.61 million shares, which may suggest that institutions feel bullish about the stock.Current Cash as of March 9, 2018
- Pro-forma cash of $14.2 million
- $7.6 million as of January 31, 2018
- $6.6 million in proceeds from warrant exercises after the end of the quarter
Expired Reverse Split
Another super bullish fact is that the company let an already approved reverse split expire. I asked the company about this and their response was:“Regarding the expired reverse stock split, the company and its shareholders did not feel such an action would be in the best interest of the shareholders once the company was able to bring the company back into compliance with the NYSE American’s continued listing standards. The company is optimistic that it will be in compliance for continued listing standards regarding its share price by the June deadline.”Source: Mail from BiopharmX, Investor Relations Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators also suggest that BioPharmX Corporation (BPMX) , is undervalued. A potential Buy is very possible for BioPharmX Corporation by a major Drug chain like CVS or Walgreens Pharmacy. CWEB Analysts have Reiterate a Buy Rating for BioPharmX Corporation (BPMX) and a Price Target of $7 within 12 months.
[youtube https://www.youtube.com/watch?v=9TXBP1t2rUc&w=560&h=315]
Comments
Post a Comment